Part 1: The Market Reality Behind Analytical Similarity The Patent Cliff Driving a $185 Billion Opportunity The global biosimilar market […]

A deep-dive for pharma/biotech IP counsel, formulary directors, health economics leads, and institutional investors The Scale of the Problem: Spending

A technical deep-dive into how biosimilar competition is reshaping R&D investment, patent strategy, and lifecycle management across the biopharmaceutical industry.

The Two-Day Gap That Reveals a System Count the days in any calendar quarter. January through March totals 90. April

From ANDA deficiency patterns and Paragraph IV litigation calculus to QbD design spaces, nitrosamine compliance, and AI-driven bioequivalence prediction. A

1. Executive Strategic Assessment: The Myth of Decoupling The global pharmaceutical supply chain currently operates under a pervasive cognitive dissonance.

Key Takeaways (Executive Summary) Part I: The Economics of Erosion The Price Destruction Mechanics Every Portfolio Manager Must Quantify The

The Uncomfortable Truth About Drug Discovery Here is a number that should bother every executive in the pharmaceutical industry: $2.6

A Ranked Investigation Into the Drug Industry’s Most Enduring IP Fortresses — and What They Cost You Pharmaceutical patents are